Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
50
KZIA Quote, Financials, Valuation and Earnings
Last price:
$8.48
Seasonality move
:
-1.27%
Day range:
$7.90 - $8.87
52-week range:
$2.86 - $17.40
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
381.81x
P/B ratio:
2.19x
Volume:
159.4K
Avg. volume:
233K
1-year change:
101.19%
Market cap:
$95.8M
Revenue:
$27.2K
EPS (TTM):
-$6.67
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
KZIA
Kazia Therapeutics Ltd.
|
-- | -- | -- | -- | $18.94 |
|
ATHE
Alterity Therapeutics Ltd.
|
-- | -- | -- | -- | $11.00 |
|
CSLLY
CSL Ltd.
|
-- | -- | -- | -- | -- |
|
IMMP
Immutep Ltd.
|
-- | -- | -- | -- | $9.50 |
|
LVCLF
Algorae Pharmaceuticals Ltd.
|
-- | -- | -- | -- | -- |
|
SPHRY
Starpharma Holdings Ltd.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
KZIA
Kazia Therapeutics Ltd.
|
$8.45 | $18.94 | $95.8M | -- | $0.00 | 0% | 381.81x |
|
ATHE
Alterity Therapeutics Ltd.
|
$3.44 | $11.00 | $62.4M | -- | $0.00 | 0% | 3.58x |
|
CSLLY
CSL Ltd.
|
$52.11 | -- | $50.6B | 36.28x | $0.81 | 2.8% | 3.31x |
|
IMMP
Immutep Ltd.
|
$2.80 | $9.50 | $407.6M | -- | $0.00 | 0% | 153.33x |
|
LVCLF
Algorae Pharmaceuticals Ltd.
|
$0.0079 | -- | $13.3M | -- | $0.00 | 0% | 0.14x |
|
SPHRY
Starpharma Holdings Ltd.
|
$3.15 | -- | $131.7M | -- | $0.00 | 0% | 14.62x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
KZIA
Kazia Therapeutics Ltd.
|
-6.76% | 4.448 | 5.57% | 0.07x |
|
ATHE
Alterity Therapeutics Ltd.
|
-- | 2.224 | -- | -- |
|
CSLLY
CSL Ltd.
|
39.2% | -0.064 | -- | 0.84x |
|
IMMP
Immutep Ltd.
|
-- | 0.527 | -- | -- |
|
LVCLF
Algorae Pharmaceuticals Ltd.
|
-- | -3.348 | -- | -- |
|
SPHRY
Starpharma Holdings Ltd.
|
9.65% | 3.556 | -- | 4.93x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
KZIA
Kazia Therapeutics Ltd.
|
-- | -- | -784.09% | -1083.16% | -- | -- |
|
ATHE
Alterity Therapeutics Ltd.
|
-- | -- | -- | -- | -- | -- |
|
CSLLY
CSL Ltd.
|
$4.3B | $2B | 8.85% | 14.06% | 33.52% | -- |
|
IMMP
Immutep Ltd.
|
-- | -- | -- | -- | -- | -- |
|
LVCLF
Algorae Pharmaceuticals Ltd.
|
-- | -- | -- | -- | -- | -- |
|
SPHRY
Starpharma Holdings Ltd.
|
-- | -- | -40.48% | -43.48% | -- | -- |
Kazia Therapeutics Ltd. vs. Competitors
-
Which has Higher Returns KZIA or ATHE?
Alterity Therapeutics Ltd. has a net margin of -- compared to Kazia Therapeutics Ltd.'s net margin of --. Kazia Therapeutics Ltd.'s return on equity of -1083.16% beat Alterity Therapeutics Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital KZIAKazia Therapeutics Ltd.-- -- -$6.3M ATHEAlterity Therapeutics Ltd.-- -- -- -
What do Analysts Say About KZIA or ATHE?
Kazia Therapeutics Ltd. has a consensus price target of $18.94, signalling upside risk potential of 124.09%. On the other hand Alterity Therapeutics Ltd. has an analysts' consensus of $11.00 which suggests that it could grow by 219.68%. Given that Alterity Therapeutics Ltd. has higher upside potential than Kazia Therapeutics Ltd., analysts believe Alterity Therapeutics Ltd. is more attractive than Kazia Therapeutics Ltd..
Company Buy Ratings Hold Ratings Sell Ratings KZIAKazia Therapeutics Ltd.1 0 0 ATHEAlterity Therapeutics Ltd.1 0 0 -
Is KZIA or ATHE More Risky?
Kazia Therapeutics Ltd. has a beta of 1.775, which suggesting that the stock is 77.474% more volatile than S&P 500. In comparison Alterity Therapeutics Ltd. has a beta of 0.114, suggesting its less volatile than the S&P 500 by 88.643%.
-
Which is a Better Dividend Stock KZIA or ATHE?
Kazia Therapeutics Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alterity Therapeutics Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kazia Therapeutics Ltd. pays -- of its earnings as a dividend. Alterity Therapeutics Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KZIA or ATHE?
Kazia Therapeutics Ltd. quarterly revenues are --, which are smaller than Alterity Therapeutics Ltd. quarterly revenues of --. Kazia Therapeutics Ltd.'s net income of -- is lower than Alterity Therapeutics Ltd.'s net income of --. Notably, Kazia Therapeutics Ltd.'s price-to-earnings ratio is -- while Alterity Therapeutics Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kazia Therapeutics Ltd. is 381.81x versus 3.58x for Alterity Therapeutics Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KZIAKazia Therapeutics Ltd.381.81x -- -- -- ATHEAlterity Therapeutics Ltd.3.58x -- -- --
-
Which has Higher Returns KZIA or CSLLY?
CSL Ltd. has a net margin of -- compared to Kazia Therapeutics Ltd.'s net margin of 24.44%. Kazia Therapeutics Ltd.'s return on equity of -1083.16% beat CSL Ltd.'s return on equity of 14.06%.
Company Gross Margin Earnings Per Share Invested Capital KZIAKazia Therapeutics Ltd.-- -- -$6.3M CSLLYCSL Ltd.52.1% $2.07 $32.5B -
What do Analysts Say About KZIA or CSLLY?
Kazia Therapeutics Ltd. has a consensus price target of $18.94, signalling upside risk potential of 124.09%. On the other hand CSL Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Kazia Therapeutics Ltd. has higher upside potential than CSL Ltd., analysts believe Kazia Therapeutics Ltd. is more attractive than CSL Ltd..
Company Buy Ratings Hold Ratings Sell Ratings KZIAKazia Therapeutics Ltd.1 0 0 CSLLYCSL Ltd.0 0 0 -
Is KZIA or CSLLY More Risky?
Kazia Therapeutics Ltd. has a beta of 1.775, which suggesting that the stock is 77.474% more volatile than S&P 500. In comparison CSL Ltd. has a beta of 0.771, suggesting its less volatile than the S&P 500 by 22.939%.
-
Which is a Better Dividend Stock KZIA or CSLLY?
Kazia Therapeutics Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CSL Ltd. offers a yield of 2.8% to investors and pays a quarterly dividend of $0.81 per share. Kazia Therapeutics Ltd. pays -- of its earnings as a dividend. CSL Ltd. pays out 43.93% of its earnings as a dividend. CSL Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios KZIA or CSLLY?
Kazia Therapeutics Ltd. quarterly revenues are --, which are smaller than CSL Ltd. quarterly revenues of $8.2B. Kazia Therapeutics Ltd.'s net income of -- is lower than CSL Ltd.'s net income of $2B. Notably, Kazia Therapeutics Ltd.'s price-to-earnings ratio is -- while CSL Ltd.'s PE ratio is 36.28x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kazia Therapeutics Ltd. is 381.81x versus 3.31x for CSL Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KZIAKazia Therapeutics Ltd.381.81x -- -- -- CSLLYCSL Ltd.3.31x 36.28x $8.2B $2B
-
Which has Higher Returns KZIA or IMMP?
Immutep Ltd. has a net margin of -- compared to Kazia Therapeutics Ltd.'s net margin of --. Kazia Therapeutics Ltd.'s return on equity of -1083.16% beat Immutep Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital KZIAKazia Therapeutics Ltd.-- -- -$6.3M IMMPImmutep Ltd.-- -- -- -
What do Analysts Say About KZIA or IMMP?
Kazia Therapeutics Ltd. has a consensus price target of $18.94, signalling upside risk potential of 124.09%. On the other hand Immutep Ltd. has an analysts' consensus of $9.50 which suggests that it could grow by 239.29%. Given that Immutep Ltd. has higher upside potential than Kazia Therapeutics Ltd., analysts believe Immutep Ltd. is more attractive than Kazia Therapeutics Ltd..
Company Buy Ratings Hold Ratings Sell Ratings KZIAKazia Therapeutics Ltd.1 0 0 IMMPImmutep Ltd.1 0 0 -
Is KZIA or IMMP More Risky?
Kazia Therapeutics Ltd. has a beta of 1.775, which suggesting that the stock is 77.474% more volatile than S&P 500. In comparison Immutep Ltd. has a beta of 1.756, suggesting its more volatile than the S&P 500 by 75.579%.
-
Which is a Better Dividend Stock KZIA or IMMP?
Kazia Therapeutics Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Immutep Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kazia Therapeutics Ltd. pays -- of its earnings as a dividend. Immutep Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KZIA or IMMP?
Kazia Therapeutics Ltd. quarterly revenues are --, which are smaller than Immutep Ltd. quarterly revenues of --. Kazia Therapeutics Ltd.'s net income of -- is lower than Immutep Ltd.'s net income of --. Notably, Kazia Therapeutics Ltd.'s price-to-earnings ratio is -- while Immutep Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kazia Therapeutics Ltd. is 381.81x versus 153.33x for Immutep Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KZIAKazia Therapeutics Ltd.381.81x -- -- -- IMMPImmutep Ltd.153.33x -- -- --
-
Which has Higher Returns KZIA or LVCLF?
Algorae Pharmaceuticals Ltd. has a net margin of -- compared to Kazia Therapeutics Ltd.'s net margin of --. Kazia Therapeutics Ltd.'s return on equity of -1083.16% beat Algorae Pharmaceuticals Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital KZIAKazia Therapeutics Ltd.-- -- -$6.3M LVCLFAlgorae Pharmaceuticals Ltd.-- -- -- -
What do Analysts Say About KZIA or LVCLF?
Kazia Therapeutics Ltd. has a consensus price target of $18.94, signalling upside risk potential of 124.09%. On the other hand Algorae Pharmaceuticals Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Kazia Therapeutics Ltd. has higher upside potential than Algorae Pharmaceuticals Ltd., analysts believe Kazia Therapeutics Ltd. is more attractive than Algorae Pharmaceuticals Ltd..
Company Buy Ratings Hold Ratings Sell Ratings KZIAKazia Therapeutics Ltd.1 0 0 LVCLFAlgorae Pharmaceuticals Ltd.0 0 0 -
Is KZIA or LVCLF More Risky?
Kazia Therapeutics Ltd. has a beta of 1.775, which suggesting that the stock is 77.474% more volatile than S&P 500. In comparison Algorae Pharmaceuticals Ltd. has a beta of -0.656, suggesting its less volatile than the S&P 500 by 165.606%.
-
Which is a Better Dividend Stock KZIA or LVCLF?
Kazia Therapeutics Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Algorae Pharmaceuticals Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kazia Therapeutics Ltd. pays -- of its earnings as a dividend. Algorae Pharmaceuticals Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KZIA or LVCLF?
Kazia Therapeutics Ltd. quarterly revenues are --, which are smaller than Algorae Pharmaceuticals Ltd. quarterly revenues of --. Kazia Therapeutics Ltd.'s net income of -- is lower than Algorae Pharmaceuticals Ltd.'s net income of --. Notably, Kazia Therapeutics Ltd.'s price-to-earnings ratio is -- while Algorae Pharmaceuticals Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kazia Therapeutics Ltd. is 381.81x versus 0.14x for Algorae Pharmaceuticals Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KZIAKazia Therapeutics Ltd.381.81x -- -- -- LVCLFAlgorae Pharmaceuticals Ltd.0.14x -- -- --
-
Which has Higher Returns KZIA or SPHRY?
Starpharma Holdings Ltd. has a net margin of -- compared to Kazia Therapeutics Ltd.'s net margin of --. Kazia Therapeutics Ltd.'s return on equity of -1083.16% beat Starpharma Holdings Ltd.'s return on equity of -43.48%.
Company Gross Margin Earnings Per Share Invested Capital KZIAKazia Therapeutics Ltd.-- -- -$6.3M SPHRYStarpharma Holdings Ltd.-- -- $15.9M -
What do Analysts Say About KZIA or SPHRY?
Kazia Therapeutics Ltd. has a consensus price target of $18.94, signalling upside risk potential of 124.09%. On the other hand Starpharma Holdings Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Kazia Therapeutics Ltd. has higher upside potential than Starpharma Holdings Ltd., analysts believe Kazia Therapeutics Ltd. is more attractive than Starpharma Holdings Ltd..
Company Buy Ratings Hold Ratings Sell Ratings KZIAKazia Therapeutics Ltd.1 0 0 SPHRYStarpharma Holdings Ltd.0 0 0 -
Is KZIA or SPHRY More Risky?
Kazia Therapeutics Ltd. has a beta of 1.775, which suggesting that the stock is 77.474% more volatile than S&P 500. In comparison Starpharma Holdings Ltd. has a beta of 0.866, suggesting its less volatile than the S&P 500 by 13.401%.
-
Which is a Better Dividend Stock KZIA or SPHRY?
Kazia Therapeutics Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Starpharma Holdings Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kazia Therapeutics Ltd. pays -- of its earnings as a dividend. Starpharma Holdings Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KZIA or SPHRY?
Kazia Therapeutics Ltd. quarterly revenues are --, which are smaller than Starpharma Holdings Ltd. quarterly revenues of --. Kazia Therapeutics Ltd.'s net income of -- is lower than Starpharma Holdings Ltd.'s net income of --. Notably, Kazia Therapeutics Ltd.'s price-to-earnings ratio is -- while Starpharma Holdings Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kazia Therapeutics Ltd. is 381.81x versus 14.62x for Starpharma Holdings Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KZIAKazia Therapeutics Ltd.381.81x -- -- -- SPHRYStarpharma Holdings Ltd.14.62x -- -- --
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
47
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
54
AAOI alert for Feb 28
Applied Optoelectronics, Inc. [AAOI] is up 56.96% over the past day.
Buy
90
BNAI alert for Feb 28
Brand Engagement Network, Inc. [BNAI] is up 36.02% over the past day.
Buy
57
SEZL alert for Feb 28
Sezzle, Inc. [SEZL] is down 13.92% over the past day.
